Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21310427 | 0.84 | OPRM1 (0.33) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL23869468 | 0.84 | OPRM1 (0.33) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL25516874 | 0.83 | FDPS (0.34) | OPRM1 | |
| SCHEMBL27426367 | 0.81 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL27426362 | 0.81 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL18612461 | 0.81 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL20781969 | 0.79 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL23733433 | 0.77 | OPRM1 (0.37) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL23251113 | 0.75 | FDPS (0.39) | OPRM1 | |
| SCHEMBL14127423 | 0.75 | FDPS (0.39) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217972-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | OPRM1 4700/4885OPRD1 4564/4885OPRK1 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.